Ultimate DAPT Trial Principal Results – Ticagrelor monotherapy post PCI for reducing clinically meaningful bleeding

May 21, 2024   |  Alison Bailey, MD, FACC; Gregg W. Stone, MD, FACC; Anthony N. DeMaria, MD, MACC

Podcast
Print
Font Size
A
A
A

Ticagrelor monotherapy following one month of dual antiplatelet therapy (DAPT) outperforms 12-month DAPT (aspirin and ticagrelor) post PCI for reducing clinically meaningful bleeding with no increased thrombotic risk.

In this interview, Gregg W Stone MD, FACC and Anthony N. DeMaria MD, MACC discuss principal results from the Ultimate DAPT Trial.

Related References:

  1. Ge, Z., Kan, J., Gao, X., Raza, A., Zhang, J. J., Mohydin, B. S., Gao, F., Shao, Y., Wang, Y., Zeng, H., Feng, L., Khan, H. S., Mengal, N., Hu, C., Wang, M., Chen, L., Wei, Y., Chen, F., Stone, G. W., . . . Chen, S. L. (2024). Ticagrelor alone versus ticagrelor plus aspirin from month 1 to month 12 after percutaneous coronary intervention in patients with acute coronary syndromes (ULTIMATE-DAPT): a randomised, placebo-controlled, double-blind clinical trial. Lancet. https://doi.org/10.1016/s0140-6736(24)00473-2
Subscribe to the ACCEL Lite Podcast

Clinical Topics: Acute Coronary Syndromes, Invasive Cardiovascular Angiography and Intervention

Keywords: ACCELLite, Ticagrelor, ACC24


< Back to Listings